Kady A. Dennis

Kady A. Dennis

Auto-generated profile, based on publicly available information

Kady A. Dennis

University of Colorado Anschutz Medical Campus 1 Aurora, CO

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
ZWZachary J. Walker
Zachary J. Walker
KVKatherine F. Vaeth
Katherine F. Vaeth
ABAmber Baldwin
Amber Baldwin
DODenis J. Ohlstrom
Denis J. Ohlstrom
LRLauren T. Reiman
Lauren T. Reiman
DSDaniel W. Sherbenou
Daniel W. Sherbenou
Protein homeostasis is critical to the survival of multiple myeloma cells. Although this is targeted with proteasome inhibitors, mRNA translation inhibition has not entered trials. Recent work illustrates broad sensitivity of multiple myeloma cells to the translation inhibitor omacetaxine. We hypothesized that understanding how multiple myeloma becomes resistant will lead to the development of drug combinations to prevent or delay relapse. We generated omacetaxine resistance in H929 and MM1S multiple myeloma cell lines and compared them with parental lines. Resistant lines displayed decreased sensitivity to omacetaxine, with EC50 > 100 nmol/L, compared with parental sensitivity of 24 to 54 nmol/L. As omacetaxine inhibits protein synthesis, we performed both RNA sequencing and ribosome profiling to identify shared and unique regulatory strategies of resistance. Transcripts encoding translation factors and containing a terminal oligopyrimidine sequence in their 5’ untranslated region were translationally upregulated in both resistant cell lines. The mTOR pathway promotes the translation of terminal oligopyrimidine motif–containing mRNAs. Indeed, mTOR inhibition with Torin 1 restored partial sensitivity to omacetaxine in both resistant cell lines. The combination was synergistic in omacetaxine-naïve multiple myeloma cell lines, and a combination effect was observed in vivo. Primary multiple myeloma cells from patient samples were also sensitive to the combination. These results provide a rational approach for omacetaxine-based combination therapy in patients with multiple myeloma, which have historically shown better responses to multiagent regimens. Implications: Through the use of ribosome profiling, our findings indicate mTOR inhibition as a novel combination therapy for partnering with the translation inhibitor omacetaxine in the treatment of multiple myeloma.

10 June 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
AKAlana L. Keller
Alana L. Keller
KDKady A. Dennis
Kady A. Dennis
DODenis J. Ohlstrom
Denis J. Ohlstrom
SPSarah E. Parzych
Sarah E. Parzych
ZWZachary J. Walker
Zachary J. Walker
DSDaniel W. Sherbenou
Daniel W. Sherbenou
Multiple myeloma (MM) is plasma cell malignancy that is mostly incurable, even with recent advances in treatment such as BCMA-targeted chimeric antigen receptor (CAR) T cells and bispecific T cell–engaging antibodies (TCEs). To better understand this treatment resistance, we examined MM cells that persisted after these treatments and consistently observed CD45 upregulation as part of a resistance program. Bone marrow samples were treated ex vivo with BCMA CAR T cells, TCEs (elranatamab, SAR442257), or activated T cells, and analyzed by flow cytometry. CD45 upregulation was validated in patient samples before and after idecabtagene vicleucel therapy (anti-BCMA CAR T-cell therapy), and by using in an in vivo mouse model of disseminated MM. Persisting MM cells exhibited focal CD45 surface patches. Mechanistic studies implicated secreted HSP70, while bulk RNA-sequencing revealed increased LAG-3, IFN-γ signaling, and PD-L1 expression. These findings suggest T cell–redirecting therapy (TCRT) drives an immuno-evasive phenotype defined by CD45 upregulation and immune checkpoint activation, supporting combination strategies of TCRT with checkpoint inhibitors to overcome resistance in relapsed/refractory MM.

2 July 2025
Verified
Other
Open access
ZWZachary J. Walker
Zachary J. Walker
KVKatherine F. Vaeth
Katherine F. Vaeth
ABAmber Baldwin
Amber Baldwin
DODenis J. Ohlstrom
Denis J. Ohlstrom
LRLauren T. Reiman
Lauren T. Reiman
DSDaniel W. Sherbenou
Daniel W. Sherbenou
SigRNA Table. Genes with Significant RNA Differences between H929 and MM1S Parental and Omacetaxine Resistant Cells.

2 July 2025
Verified
Other
Open access
PDF file
ZWZachary J. Walker
Zachary J. Walker
KVKatherine F. Vaeth
Katherine F. Vaeth
ABAmber Baldwin
Amber Baldwin
DODenis J. Ohlstrom
Denis J. Ohlstrom
LRLauren T. Reiman
Lauren T. Reiman
DSDaniel W. Sherbenou
Daniel W. Sherbenou
Supplemental Table 3. Myeloma Patient Characteristics

4 August 2026
Verified
Other
Open access
AKAlana L. Keller
Alana L. Keller
KDKady A. Dennis
Kady A. Dennis
DODenis J. Ohlstrom
Denis J. Ohlstrom
SPSarah E. Parzych
Sarah E. Parzych
ZWZachary J. Walker
Zachary J. Walker
DSDaniel W. Sherbenou
Daniel W. Sherbenou
Combination Treatment of Ruxolitinib and Elranatamab was not Synergistically Cytotoxic to MM Cells

1 December 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
LPLindsey M Pale
Lindsey M Pale
ADAshna Dhoonmoon
Ashna Dhoonmoon
AHAnastasia Margaret Hale
Anastasia Margaret Hale
KDKady A Dennis
Kady A Dennis
ESEmily M Schleicher
Emily M Schleicher
GMGeorge-Lucian Moldovan
George-Lucian Moldovan
Understanding chemoresistance mechanisms in BRCA-deficient cells will allow for identification of biomarkers for predicting tumor response to therapy, as well as the design of novel therapeutic approaches targeting this chemoresistance. Here, we show that the protein MED12, a component of the Mediator transcription regulation complex, plays an unexpected role in regulating chemosensitivity in BRCA-deficient cells. We found that loss of MED12 confers resistance to cisplatin and PARP inhibitors in both BRCA1- and BRCA2-deficient cells, which is associated with restoration of both homologous recombination and replication fork stability. Surprisingly, MED12-controlled chemosensitivity does not involve a function of the Mediator complex, but instead reflects a distinct role of MED12 in suppression of the TGFβ pathway. Importantly, we show that ectopic activation of the TGFβ pathway is enough to overcome the fork protection and DNA repair defects of BRCA-mutant cells, resulting in chemoresistance. Our work identifies the MED12-TGFβ module as an important regulator of genomic stability and chemosensitivity in BRCA-deficient cells. Citation Format: Lindsey M Pale, Ashna Dhoonmoon, Anastasia Hale, Kady A Dennis, Emily M Schleicher, Claudia M Nicolae, George-Lucian Moldovan. Loss of MED12 activates the TGFβ pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr B062.